Pinealon vs Semax.

Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to the class of "peptide bioregulators" developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, who designed short peptides intended to mirror regulatory sequences associated with the pineal gland. It is a research chemical, not an approved drug.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) consisting of the ACTH(4-7) fragment of adrenocorticotropic hormone joined to a C-terminal Pro-Gly-Pro tripeptide. It was developed in the late 1980s/early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences and is first described in the scientific literature around 1991. The Pro-Gly-Pro extension stabilizes the otherwise rapidly degraded ACTH fragment without retaining ACTH's hormonal (corticosteroid-releasing) activity, making Semax a "neuropeptide" rather than a hormone.

The proposed mechanism, advanced primarily by the Khavinson group, is that short peptides like EDR penetrate cell and nuclear membranes and interact directly with DNA and chromatin to act as epigenetic modulators of gene expression and protein synthesis. In cell and biophysical studies the EDR peptide has been reported to bind deoxyribooligonucleotides/DNA and to enter the nucleus of HeLa cells, and proposed downstream effects include reduced reactive oxygen species, modulation of MAPK/ERK signaling, lowered pro-apoptotic markers (caspase-3, p53), increased antioxidant enzymes (SOD2, GPX1), and stimulation of serotonin-related (tryptophan hydroxylase) expression in cortical neurons. These are mechanistic hypotheses derived largely from in vitro and computational/biophysical work rather than from established receptor pharmacology.

Semax is structurally derived from ACTH(4-10) but lacks the melanocortin-receptor-driven hormonal effects of full-length ACTH, so it does not stimulate cortisol release. Mechanistic (largely rodent and in vitro) work indicates it upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, and modulates expression of NGF and other neurotrophic and immune-response genes, which is proposed to support neuronal survival and synaptic plasticity. A separate biochemical mechanism is inhibition of enkephalin-degrading enzymes in human serum (reported IC50 ~10 µM), which may prolong the activity of endogenous regulatory peptides. The relative contribution of each pathway to any observed clinical effect remains unsettled; Wikipedia and reviews note the precise mechanism of action is not definitively established.

There are no completed human efficacy trials of pinealon; the evidence base is preclinical (in vitro cell culture, biophysical, and rodent) and clusters heavily around a single research lineage. Reported findings include increased neuronal cell viability and suppression of free radicals in culture (Khavinson, Rejuvenation Research 2011), nuclear penetration and DNA binding of fluorescently labeled short peptides (Fedoreyeva, Biochemistry Moscow 2011), stimulation of serotonin expression in brain cortex cells (Khavinson, Bull Exp Biol Med 2014), and antioxidant/neuroprotective effects in aged-rat hypoxia and carotid-occlusion models (Mendzheritsky, Adv Gerontol 2011, 2014). A 2020 Molecules review by the developers frames EDR as a candidate neuroprotective agent for early Alzheimer's disease, but it is a hypothesis-generating review of the group's own animal and in vitro data, not clinical proof. Independent, non-affiliated replication is essentially absent, so reported effects should be treated as preliminary.

Human evidence comes almost entirely from Russian clinical research and is modest in scale. A representative controlled study by Gusev, Martynov and colleagues (Zh Nevrol Psikhiatr Im S S Korsakova, 2018; PMID 29798983) in 110 ischemic-stroke patients reported that semax plus early rehabilitation raised plasma BDNF and improved motor recovery and functional independence (Barthel index). The strongest mechanistic data, BDNF/TrkB upregulation (Brain Research, 2006; PMID 16996037) and neuroprotection and immune-gene regulation in rat ischemia (Mol Genet Genomics, 2017; PMID 28255762), are preclinical (rat/in vitro). Proposed uses such as ADHD or cognitive enhancement rest largely on hypothesis papers (e.g., Med Hypotheses, 2007; PMID 16996699) rather than rigorous trials. Crucially, no large, independent, randomized, double-blind Western trials have replicated the Russian findings, so the human cognitive- and stroke-benefit claims should be regarded as preliminary.

Documented safety data in humans are effectively nonexistent; there are no published controlled human safety or pharmacokinetic trials, and no established toxicology dossier in the peer-reviewed literature. Materials sold as "pinealon" are research chemicals not manufactured to pharmaceutical GMP standards, so identity, purity, sterility, and endotoxin content are unverified and vary by vendor. Long-term effects, immunogenicity, and any consequences of the proposed DNA-interacting mechanism are unstudied in humans. Because the compound is unapproved and unregulated for human use, its risk profile is genuinely unknown rather than established as safe.

Russian clinical reports and the intranasal route describe generally good tolerability, with mild nasal/local irritation the most commonly noted complaint; however, these data come from small studies without the long-term, independent safety surveillance expected for Western drug approval. There is no robust characterization of long-term safety, drug interactions, effects in pregnancy, or risks from non-pharmaceutical "research-use" material sold online, which may vary in purity and sterility. Because much of the mechanistic profile (BDNF/neurotrophin modulation, peptidase inhibition) is extrapolated from animal models, downstream effects of chronic human use are essentially unstudied. Product sold by online vendors is not manufactured to pharmaceutical standards and its identity and contaminants are not guaranteed.

Pinealon is not approved by the FDA or, to public knowledge, any major regulatory authority; it has no ATC code and no standard pharmaceutical identifiers (DrugBank/KEGG/UNII), and is sold only as a research-use-only chemical. It is not a recognized therapeutic and is not WADA-listed as a named substance, though related growth/peptide categories may fall under broader anti-doping provisions.

Semax is approved as a prescription drug in Russia (and appears on Russia's List of Vital and Essential Drugs) for indications including ischemic stroke, transient ischemic attack, and cognitive disorders. It is not FDA-approved and is unscheduled in the United States, where it is sold by online vendors as a research/non-pharmaceutical product; it is not approved or marketed in most countries outside Russia.